GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹10 Cr | ₹21 Cr | ₹16 Cr | ₹22 Cr | ₹13 Cr |
What is the latest Contingent Liabilities ratio of GLAND PHARMA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹10 Cr |
| Mar2025 | ₹21 Cr |
| Mar2024 | ₹16 Cr |
| Mar2023 | ₹22 Cr |
| Mar2022 | ₹13 Cr |
How is Contingent Liabilities of GLAND PHARMA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹10 Cr | -52.68 | |
| Mar2025 | ₹21 Cr | 37.24 | |
| Mar2024 | ₹16 Cr | -29.41 | |
| Mar2023 | ₹22 Cr | 72.94 | |
| Mar2022 | ₹13 Cr | - | |
Compare Contingent Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹46,618.3 Cr | -7.2% | -3.1% | 48.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,204.0 Cr | -1% | -5.5% | 5.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹238,497.0 Cr | -2.6% | -3.9% | 38.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹170,481.0 Cr | -1.7% | -10.2% | 30.5% | Stock Analytics | |
| CIPLA | ₹108,012.0 Cr | 0.9% | -3.2% | -15.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,207.0 Cr | -0.6% | 1% | -0.1% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | -7.2% |
-3.1% |
48.9% |
| SENSEX | -1.6% |
-2.3% |
-11.5% |
You may also like the below Video Courses